Skip to main content

Share story

Security Products

Microsoft sets February 2027 retirement for Entra SMS sign-in

Microsoft sets February 2027 retirement for Entra SMS sign-in Image: Primary
Microsoft will retire SMS as a first-factor sign-in method for Entra ID workforce tenants starting in February 2027 and is urging administrators to migrate affected users to passkeys or other phishing-resistant authentication. Alternatives include QR-code authentication and FIDO2 security keys. The retirement applies even when an organization uses its own telephony provider for SMS or voice-based multifactor authentication. It does not cover Azure AD B2C or Entra External ID customer-identity scenarios. Microsoft is also making passkeys the default Entra authentication experience and will prompt eligible SMS or voice users to register one as the rollout reaches their organization.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from BleepingComputer and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Security Infrastructure
Security Infrastructure

Ransomware attack halts trading on Nepal Stock Exchange

The Nepal Stock Exchange suspended all Monday trading after ransomware hit infrastructure hosting the trading systems of 72 brokerages. Data Hub detected the attack early that morning and kept affected systems offline while invest...

AI Products
AI Products

Tech groups use residual-value guarantees to lower AI financing costs

Large technology companies are increasingly using residual-value guarantees to finance AI equipment off their balance sheets, the Financial Times reports. The guarantees apply the companies' credit strength to the hardware's futur...

Capital Products
Capital Products

Novadip raises €10.4 million to complete pivotal bone-graft trial

Belgian regenerative-medicine company Novadip Biosciences has closed a €10.4 million convertible financing led by New Science Ventures. The funding will support completion of an ongoing Phase 3 trial in the United States and Europ...